2 / 7
Page 20
Notes:
Journal of Biotechnology & Biomaterials | ISSN: 2155-952X | Volume: 8
&
24
th
Biotechnology Congress: Research & Innovations
CRISPR Cas9 Technology and Genetic Engineering
Annual Congress on
October 24-25, 2018 | Boston, USA
Recombinant proteins: From bench to clinics
R
ecombinant proteins from the use of DNA technology are found in essentially every western pharmacy, medical testing
laboratory, and biological research laboratory. One major issue regarding the clinical use of many peptides is their short
half-life due to the rapid clearance from the circulation. To overcome this problem, we succeeded to ligate the signal sequence of
O-linked oligosaccharides to the coding sequence of the hormones. The cassette gene that has been used contains the sequence
of the carboxyl-terminal peptide (CTP) of human chorionic gonadotropin
β
(hCG
β
) subunit. The CTP contains 28 amino
acids with four O-linked oligosaccharide recognition sites. It was postulated that O-linked oligosaccharides add flexibility,
hydrophilicity, and stability to the protein. On the other hand, it was suggested that the four O-linked oligosaccharides play an
important role in preventing plasma clearance and thus increasing the half-life of the protein in circulation. Using this strategy
we succeeded to ligate the CTP to the coding sequence of follitropin (FSH), thyrotropin (TSH), erythropoietin (EPO) growth
hormone (GH) and thus to increase the longevity and bioactivity of these proteins in-vivo. Interestingly, the new analogs of
FSH and GH were found not immunogenic in human and it is already passed successfully clinical trials phase III and phase II
respectively. Moreover, FSH long-acting was approved by the European Commission (EC) for treatment of fertility. In addition,
our results indicated that long-acting GH is not toxic in monkeys and the results from the clinical trials phase I and phase II
seem to be promising. Designing long-acting peptides will diminish the cost of these drugs and perhaps reduce the number of
injections in the clinical protocols.
Biography
Fuad Fares have completed his MSc and DSc studies at the Faculty of Medicine, Technion-Israel Institute of Technology, and postdoctoral studies at the Department
of Molecular Biology and Pharmacology, School of Medicine, Washington University, St. Louis Missouri, USA. He developed the Molecular Genetic Laboratory at
Carmel Medical Center, Haifa, Israel. Now he is the head of Molecular Genetic Laboratory at the Department of Human Biology, University of Haifa, Israel. He
published more than 100 manuscripts in reputed journals and 12 patents. He served as a member of the Israel Council for Higher Education last 15 years. Moreover,
he is the founder and the inventor of PROLOR Biotech Company for “designing long-acting recombinant proteins”. PROLOR had an exit to OPKO Health Company
in the USA. He developed long-acting FSH in the USA and this hormone (ELONVA) is marketed since 2010 by Merck Germany.
ffares@sci.haifa.ac.ilFuad Fares
University of Haifa, Israel
Fuad Fares, J Biotechnol Biomater 2018, Volume 8
DOI: 10.4172/2155-952X-C4-096